PARIS (Reuters) – Sanofi (NASDAQ:) said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R).
The French pharmceutical company said its Opella business has been valued at around 16 billion euros ($17.38 billion), or 14 times EBITDA in 2024, and French public investment bank Bpifrance is expected to take a stake of around 2%.
The proposed transaction, still subject to definitive agreements and customary statutory approvals, is expected to close in the second quarter of 2025 at the earliest, it added.
($1 = 0.9206 euros)
